Life sciences market overview
The life sciences industry focuses on improving the health and well-being of people, animals and the environment. It includes companies and organizations that study how living things work and develop new medicines, medical devices and technologies to treat diseases and enhance quality of life. From discovering new treatments to producing vaccines and improving food safety, the life sciences play a vital role in everyday health and well-being.
This industry continues to be a robust and rapidly evolving global market. As of 2023, it was valued at $412.74 billion, encompassing major sectors like biotechnology, pharmaceuticals and healthcare services. Among these, the biotechnology sector is seeing especially rapid growth. Thanks to cutting-edge research and rising worldwide demand for better treatments and diagnostics, the biotech market alone is projected to soar to $727.1 billion in 2025.
As innovation accelerates and global health needs expand, the life sciences industry is poised to remain at the forefront of scientific and economic progress.
Insurance implications for Life Sciences
Top life science clusters in the United States include established hubs in Boston, San Francisco, San Diego and emerging clusters include both Pittsburgh and Houston. Life science businesses in these major markets – from early-stage start-ups to multinational corporations – face unique and complex risks that require tailored insurance solutions. These risks span across research, manufacturing, clinical trials and global distribution.
How Life Sciences innovation is shaping the insurance industry
As the life sciences industry advances, it is also transforming the insurance landscape. New breakthroughs in biotechnology, personalized medicine and diagnostics are enabling earlier detection and more effective treatment of diseases, which can lead to improved health outcomes and reduced long-term healthcare costs. For insurers, this means a shift in how risks are assessed, premiums are calculated, and policies are structured.
One major change is the rise of personalized medicine, where treatments are tailored to an individual’s genetic makeup. This level of precision allows for better disease prevention and management but also challenges insurers to update underwriting models and coverage plans. In the future, policies may become more customized, reflecting an individual’s unique health profile and risk factors.
Additionally, innovations such as wearable health devices and real-time health monitoring – often developed through life sciences research – are providing insurers with more accurate, up-to-date data. This helps improve risk prediction and may lead to discounts or incentives for healthy behaviors, much like usage-based car insurance.
At the same time, the rapid pace of change raises ethical and regulatory questions, particularly around data privacy, genetic testing and access to care. Insurers, regulators and life sciences companies must work together to ensure that innovations benefit consumers without creating discrimination or inequity.
Looking ahead: A shift from reactive coverage to proactive protection
As life sciences continue to push the boundaries of what’s possible in healthcare, insurance companies are actively evolving to keep pace. The future of insurance will likely be shaped by deeper integration of health data, AI-driven risk models, and more flexible, consumer-centered policies.
Historically, insurance has been a reactive force – stepping in to cover losses after illness, injury, or error. But looking ahead, we can expect a fundamental shift: insurers and healthcare partners becoming more proactive, focusing not just on covering illness, but helping to prevent it.
This evolution is being driven by trends including advancements in health data and analytics, allowing insurers to identify risks earlier and offer tailored prevention programs. Partnerships with life sciences and healthcare innovators are allowing insurers to integrate prevention directly into patient journeys.
This proactive approach opens new doors for innovation in risk management, wellness initiatives, and customer engagement – particularly in areas like chronic disease management, mental health, and personalized medicine. As a result, there are multiple types of insurance solutions, such as Business Owner’s Policies (BOP), Commercial Package Policies (CPP) and Global Insurance Programs (with local admitted policies as needed).
As a wholesale broker, Bridge Specialty Group is informed and equipped to place these types of coverage. We have both the markets and relationships established to do so effectively and competitively.
Key liability considerations
Products liability
- Standard policies often limit coverage to products that are “sold.”
- Life Science-specific forms broaden the definition of “Your Product” to include those used in both demonstrations and clinical trials
Clinical trial liability
- Companies involved in clinical trials (as sponsors or not) require:
- Life Science Products Liability with clinical trial exposure coverage
- Medical Monitoring Expense coverage even without a confirmed bodily injury
Key property considerations
Business income for research and development
- Traditional BI policies use Net Profit as the valuation basis.
- R&D companies, often operating at a loss, need coverage that removes “Net Profit” language to allow reimbursement for lost R&D time and efforts.
Spoilage / Temperature change / Contamination
- Temperature-sensitive materials are common in this sector.
- Specialized policies include coverage for:
- Spoilage due to temperature fluctuations
- Contamination risks
Property in transit
- Products in transit, especially for clinical trials, may not be covered under standard policies.
- Ocean Cargo policies are often required for global shipments.
Specialty Property coverage
- Includes protection for scientific animals, specialized equipment and other unique property exposures.
Types of Life Science risks covered
- Pharmaceutical & Biotechnology Manufacturers
- Medical Device & IVD (In-Vitro Diagnostics) Manufacturers
- Clinical Research Organizations (CROs)
- Contract Manufacturers & Service Providers
- Dietary Supplement & Cosmetic Manufacturers
- Dental Equipment & Supplies Manufacturers
- Analytical/Medical Laboratories
- Veterinary Product Manufacturers (including medicated feeds, vaccines)
Conclusion: A converging future of health and finance
The life sciences industry is not only advancing our understanding of health and disease – it’s also reshaping how we think about risk, care and protection. As biotechnology, personalized medicine and digital health tools become more sophisticated, the insurance industry must adapt to stay relevant and responsive. The result is a future where insurers move beyond financial safety nets to become partners in long-term health and wellness.
Collaboration between life sciences innovators, insurers and regulators will be key to building systems that are fair, data-driven and centered on improving quality of life. For individuals, this means more tailored, proactive coverage. For society, it marks a step toward a more integrated and intelligent healthcare ecosystem.
Author
Dan Pardo, Associate Casualty Broker
Based in Boston, Massachusetts, Dan Pardo brings over 15 years of industry-specific experience across both retail and wholesale markets. Working as an Associate Casualty Broker for Bridge Specialty Group, Dan specializes in tailored solutions for risks such as General Liability, Monoline Products Liability, Excess Liability and Limits and complex global casualty programs, supporting a wide spectrum of life science clients, from early R&D to commercialized enterprises with a global footprint.
For more information about life sciences coverage, contact Dan at (617) 694-5262 or [email protected]
This material has been prepared for general informational purposes only, is intended to apply generally rather than to any specific company and presumes appropriate discretion will be exercised regarding any particular situation.
©2025 Copyright Bridge Specialty Group. All Rights Reserved.
